Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Brain tumor, child: PNET
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 33 for your search:
Start Over
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 50 and under
Sponsor: NCI, Other
Protocol IDs: AEWS1031, NCI-2011-02611, COG-AEWS1031, CDR0000687639, U10CA098543, NCT01231906
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 2013-062, NCI-2013-02001, P30CA022453, NCT01987596
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0912, COG-ADVL0912, CDR0000647587, NCT00939770
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 30
Sponsor: Other
Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: Re-MATCH, W81XWH-10-1-0089, CDMRP-PRO93877, NCT01326104
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED12689, U1111-1128-5704, NCT01751308
WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-2014-00547, ADVL1312, UM1CA097452, NCT02095132
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 2 to 21
Sponsor: Other
Protocol IDs: 14.0855, NCT02332889
High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 and under
Sponsor: Other
Protocol IDs: PNET HR, NCT00180791
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Children
Sponsor: Other
Protocol IDs: 2005-12-009, NCT00798811
Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years
Phase: Phase II
Type: Treatment
Status: Active
Age: 5 to 19
Sponsor: Other
Protocol IDs: PNET HR+ 5, CSET 1329, NCT00936156
Antineoplaston Therapy in Treating Children With Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2011-02605, CDR0000686608, COG-ACNS0821, ACNS0821, U10CA180886, U10CA098543, NCT01217437
Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SNUCH-SCT-1102, NCT01342237
Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents
Phase: Phase II
Type: Treatment
Status: Active
Age: 19 and under
Sponsor: Other
Protocol IDs: SNUCH-1201, NCT01535183
Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 25
Sponsor: Other
Protocol IDs: 06-1151, NCT01542736
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: RADBEV, NCI-2011-01149, NCT00756340
Study of Busulfan for Refractory Central Nervous System (CNS) Tumors
Phase: Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 21
Sponsor: Other
Protocol IDs: CNS 1100, NCT00836628
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 22
Sponsor: Pharmaceutical / Industry
Protocol IDs: 07-098, NCT00634231
Photodynamic Therapy (PDT) for Brain Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: 163588-1, NCT01682746
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
Phase: Phase I
Type: Supportive care, Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: NYMC-165, NCT02164097
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: NCI, Other
Protocol IDs: PBTC-042, U01CA081457, NCT02255461
Start Over